Flow cytometric analysis of platelets type 2 diabetes mellitus reveals ‘angry’ platelets

Prashilla Soma, Albe Carina Swanepoel, Jeanette Noel du Plooy, Thandi Mqoco and Ethesia Pretorius*

Abstract

Background: The function of platelets have extended way beyond the horizon of haemostasis and thrombosis, and are recognised as active participants in vascular inflammation, as well as in prothrombotic complications of cardiovascular diseases. We describe and compare platelet function in type II diabetes (with and without cardiovascular manifestation) and healthy individuals using scanning electron microscopy and flow cytometry.

Methods: Thirty subjects were recruited per group and informed consent was obtained from all participants. Diabetic patients were recruited from the diabetic clinic of the Steve Biko Academic Hospital (South Africa). Blood samples were drawn from all participants so that platelet specific antigens were analyzed in citrated whole blood. The platelet parameters used in the study were platelet identifiers (CD41 and CD42) and markers of platelet activation (CD62 and CD63).

Results: Results show that, compared to healthy individuals, both diabetic groups showed a significant difference in both platelet identifiers (CD41-PE, CD42b-PE) as well as markers indicating platelet activation (CD62P-PE and CD63-PE).

Interpretation: The flow cytometric data shows that the platelet surface receptors and platelet activation are statistically elevated. This is suggestive of enhanced platelet activation and it appears as if platelets are displaying ‘angry’ behaviour. The lysosomal granules may play a significant role in diabetes with cardiovascular complications. These results were confirmed by ultrastructural analysis.

Background

It is plausible to underestimate the impact of platelets in clinical medicine, when one considers that these blood cells are only 1.5–3 μm in size, survive for approximately 8–10 days, and are mere fragments of megakaryocyte cytoplasm [1–3]. The function of platelets have extended way beyond the horizon of haemostasis and thrombosis. In fact, they are now recognised as active participants in initiating and sustaining vascular inflammation as well as in prothrombotic complications of cardiovascular diseases [1]. Platelets have been assigned multiple attributes and have been described in inflammatory conditions such as atherosclerosis, arthritis and tumour metastasis [1]. Due to the multifunctional role of platelets, they are an accessible and important inflammatory marker for disease pathophysiology [4, 5]. Platelets are activated when they are in contact with damaged vascular endothelium [5], and once activated, they are able to secrete a wide spectrum of inflammatory mediators that exert both local and systemic effects [6]. Platelet activation is also the mechanism implicated in the pathogenesis of chronic medical conditions such as atherosclerosis, coronary vascular disease and cerebrovascular disease [3]. Due to inflammation there is an imbalance between procoagulant and anticoagulant properties of the endothelium with subsequent local stimulation of the coagulation cascade [7]. Another feature of inflammation is a multitude of interactions between leukocytes, endothelial cells and platelets. More importantly, regardless of its aetiology, inflammation causes endothelial activation [7]. In diabetes mellitus, endothelial dysfunction is one of the mechanism ascribed to increased atherothrombotic risk [8]. With...
cigarette smoking, the endothelium becomes activated and induces the intrinsic coagulation pathway. This results in platelet activation and enhanced platelet aggregation, which in turn causes thrombin stimulation and fibrin formation [9]. Abnormal platelet activation, platelet count and volume have been implicated as risk factors of ischaemic stroke [10].

Once platelets are activated, they initiate reactions whereby changes in the level of expression of surface glycoproteins (GP) results, which act as receptors for platelet agonists and for adhesive proteins, involved in platelet aggregation. Platelet activity can be measured using various fluorescently labelled markers in flow cytometry. As flow cytometry allows the simultaneous detection of surface antigens in a sensitive and specific manner, it is therefore possible to examine aspects of the platelet membrane activity—see Table 1 for examples of available platelet markers.

### Platelets in inflammatory conditions

There is a strong indication that platelets also have relevant functions in inflammation [11]. In fact, it was shown that thrombosis and inflammation share many key molecular mechanisms and that they are fundamentally linked processes [7]. It is now recognised that vascular inflammation is the key underlying mechanism in atherogenesis and atheroprosession. The evidence of platelets being fundamental mediators in the initiation and maintenance of a chronic proinflammatory milieu is provided by the direct interactions with inflammatory cells and secretion of autocrine and paracrine effector molecules [12]. Another emerging concept is the significant role of platelet-mediated recruitment of leukocytes in the propagation, progression and pathogenesis of atherosclerotic disease. Platelets can interact with leukocytes: (a) during haemostasis, when there is vascular damage and recruit leukocytes to the growing thrombus, (b) when endothelial cells are stimulated thereby adhering and activating platelets and then bridge blood-borne leukocytes to the vessel wall and (c) in the formation of heterotypic aggregates prior to contact with endothelial cells when adhesion between platelets and leukocytes occur in the blood [13].

It is well known that in subjects with type 2 diabetes mellitus, function of platelets is impaired. In fact, a subthreshold stimuli is needed to activate platelets which are constantly in activation despite the lack of a major plaque event and have thus been defined as ‘angry platelets’ [14]. This is significant as it has been postulated that circulating platelets in subjects with untreated type 2 diabetes mellitus are in a hyperactive state and are implicated as etiologic factors in thrombotic complications [15] which are accelerated in diabetics [16]. Of note is the finding of hyperactive platelets in metabolically controlled diabetics without cardiovascular complications [17]. In addition, expression of P-selectin is increased on the surface of platelets in patients presenting with symptomatic coronary artery disease, making it a marker of ‘angry platelets’ [18].

Diabetes with cardiovascular complication may also lead to acute conditions like thrombo-embolic ischemic stroke. Multiple studies regarding the activity of platelets in acute stroke have been performed. Results obtained from these studies (acute ischaemic stroke) showed increased mean platelet volume, platelet aggregation enhancement in post-ischaemic stroke, increased α-and dense granule release and statistically significant increase in expression of P-selectin (CD62P), CD63, and thrombospondin [19]. The study by Marquardt and co-workers investigated the time course of platelet activation after ischaemic stroke. They found a significant increase in CD62P and CD63 expression within 24 h post cerebral ischaemia. In addition, it was also shown that CD62P expression declines during the first weeks after stroke, whereas CD63 expression remains increased for at least 3 months after stroke [20].

Another confounding factor together with diabetes is cigarette smoking. Multiple studies provides evidence on the many adverse effects of smoking on the cardiovascular system. This includes: (a) it causes endothelial

| Cluster of differentiation | Glycoprotein (GP) | Function |
|----------------------------|------------------|----------|
| CD41                       | GPIIb            | Anti-CD41a reacts with platelet membrane GPIIb in the intact complex with GPIIa but not with GPIIb or GPIIa separately. Useful in the identification and enumeration of platelets |
| CD42                       | GPIb             | Anti-CD42b reacts with platelet membrane GPIb |
| CD62                       | P-Selectin       | Anti-CD62 reacts with α-granule membrane protein which is expressed on the surface of activated platelet |
| CD63                       | GPIV             | Anti-CD63 reacts with lysosomal granule-membrane glycoprotein that is expressed on surface of activated platelet |

In this study CD41-FITC (fluorescein isothiocyanate) and CD41, CD42b, CD62, CD63-PE (phycoerythrin) was used
dysfunction [21, 22]; (b) increases inflammation [23]; (c) it alters the lipid profile and creates an atherogenic setting; (d) promotes atherosclerotic progression by enhancing oxidative stress, lipid peroxidation and mitochondrial damage [23, 24]; (e) it destabilizes atherosclerotic plaque by increasing matrix metalloproteinases [25]; (f) increases platelet activation and activates coagulation cascade with subsequent atherothrombosis [26, 27]. Flow cytometric findings in the research by Al-Dahr, showed a decrease in CD41b with an increase in CD40 and CD62 [28]. This paper, therefore investigates the functional role of platelets in diabetes, with and without cardiovascular involvement using flow cytometry and scanning electron microscopy to look at platelet ultrastructure.

Methods
Participants
Thirty healthy individuals were used as controls. These individuals were non-smokers, who did not use any chronic medication and did not have a history of thrombotic disease. Sixty diabetic subjects (type 2) were recruited from the Steve Biko Academic Hospital, diabetic clinic in South Africa. Inclusion criteria included: (a) subjects older than 18 years and willing to provide informed consent, (b) subjects with known diagnosis of diabetes, (c) for the cardiovascular group, history of previous myocardial infarction, peripheral arterial disease, stroke or coronary arterial bypass grafting. Exclusion criteria included: (a) subjects hemodynamically unstable and (b) subjected with documented life threatening complications. Five milliliters of blood was drawn into a citrate tube, from each participant. Ethical clearance was obtained for this study from the University of Pretoria Human Ethics Committee. Informed consent was obtained from all participants.

Ultrastructural analysis
Scanning electron microscopy was used to prepare platelets from platelet rich plasma (PRP) according to previously described methods [29]. Platelets from individuals with diabetes, cerebrovascular disease and smoking were compared to platelets from healthy individuals.

Flow cytometry
For each blood sample taken four tubes was prepared; each tube containing 1 ml sheath fluid from Beckmann and Coulter and 20 µl of blood. The various tubes were stained with 20 µl of CD41-FITC (fluorescein isothiocyanate) and 20 µl of one of the following probes: CD41-PE (phycoerythrin), CD42b-PE, CD62P-PE and CD63-PE (from Beckman Coulter). The samples stained with different probes, were incubated at room temperature in the dark for 20 min before being analyzed by a flow cytometer (FC 500, Beckman Coulter). The surface expression of platelet receptors was determined by flow cytometry using the different monoclonal antibodies as indicated in Table 1.

Forward scatter and 90º side scatter were displayed on logarithmic scales. Two platelet gates were set. The first gate was set according to the morphological characteristics of platelets while the second gate was set according to CD41-FITC fluorescence, a platelet specific marker. The fluorescence of the different antibodies was plotted on 256-channel log histograms. The results were expressed in arbitrary units as mean channel fluorescence intensity (MCFI).

Statistical analysis
For each participant the MCFI was calculated as the mean fluorescence of a large sample of platelets (10,000 platelets per individual), the well-known Central Limit Theorem assures us that the Normal distribution is a close approximation for the distribution of the MCFIs for the experimental groups. GraphPad Prism 5 was employed to perform one-way ANOVA for all statistical analysis, with a p value of ≤0.005 considered significant. Post-hoc Dunnett’s Multiple Comparison Test was performed to compare the two diabetic groups to the controls.

Results
Table 2 shows the demographic data of our study population. SEM analysis of the platelets from the three groups showed that there is a progressive change in platelet structure between the groups. Representative micrographs of the ultrastructure of platelets from healthy individuals, and individuals with diabetes (with and without cardiovascular manifestations), are shown in Fig. 1. Healthy platelets prepared for SEM, typically show slight contact activation, where minimal pseudopodia formation is visible (Fig. 1a). However, during inflammation, platelets form numerous pseudopodia, with microparticle formation, as well as spreading and extensive clumping, which is the hallmark of over- or hyperactivation. This hyperactivation is seen in platelets from individuals with diabetes with and without CVD (Fig. 1b, c). However, diabetic patients with CVD are characterised by an increased presence of hyperactivation and microparticle formation Fig. 1c. Following the ultrastructural analysis we performed flow cytometry on the control and two diabetic groups. We found that the ultrastructural results were fully supported by the flow cytometry results discussed below.
CD41-PE and CD42b-PE MCFI were significantly elevated in both diabetic groups when compared to healthy individuals (p value <0.001). CD62P-PE and CD63-PE MCFI were significantly decreased for both diabetic groups. The percentage activated platelets indicated with CD62P-PE and CD63-PE were significantly increased in both the diabetic groups. It should be noted that the platelet activation indicated CD63-PE showed the diabetic group with cardiovascular complication to have the largest percentage of activated platelets.

Discussion

Diabetes

Increased expression of platelet activation markers CD31, CD36, CD49b, CD62P and CD63 was confirmed by Eibl and co-workers when type 2 diabetics were compared with normal individuals [30]. In fact, increased expression of CD63 and CD62, enhanced platelet activation, and aggregation are viewed as one of the major causes of atherosclerosis and thrombosis in diabetes [31]. CD62P is found in the α-granules of platelets and are used as markers for activated platelets, while their absence suggests a resting state [32]. A feature that appears strongly in diabetics is that of platelet hyperaggregation. This is prevalent in both type 1 and type 2 diabetics [33]. From a pathophysiological view, this is significant as hyperaggregated platelets have a tendency to block blood vessels [5], contributing to atherothrombotic complications in diabetics. CD63 is a 53 kDa lysosomal membrane protein identified on surface of activated platelets after release reaction [34, 35].

Prevention of early platelet adhesion to the damaged vessel wall by blocking platelet surface receptors GPIbα or GPVI protects from stroke without provoking bleeding complications. In addition, downstream signalling of GPIba and GPVI has a key role in platelet calcium homeostasis and activation [36]. The CD42b MoAb used in this research, specifically binds to the platelet GPIba. GPIba forms part of the GPIb-IX-V complex which is the receptor for von Willebrand’s factor and is known as von Willebrand’s factor-dependant adhesion receptor. According to De Meyer and co-workers in 2011, the importance of GPIba far exceeds that of VWF in arterial thrombosis and GPIba is a central receptor in different vascular processes of thrombosis and inflammation, all of which may contribute to the progression of ischemic stroke [37]. Furthermore, engagement of GPIb-IX-V by von Willebrand factor (VWF) mediates platelet adhesion to damaged vessels and triggers platelet activation and thrombus formation in heart attacks and stroke [38].

Flow cytometric analysis found a significant increase in platelet activation regarding CD62 (P-selectin) for the diabetics group while the CD62 MCFl values decreased compared to the controls as shown in Table 3. This unexpected finding may be attributed to the fact that P-selectin can be cleaved from the membrane surface after activation releasing P-selectin into the plasma known as soluble P-selectin (sP-selectin). The exact mechanism of this shedding is unknown but several mechanisms have been suggested including cleavage by serum proteases or non-specific enzymes or by simple shedding [39]. However, studies have shown an increase in both P-selectin on the surface of platelets and sP-selectin indicating that diabetes with or without cardiovascular complications are associated with chronic activation of platelets as P-selectin is being shed from activated platelets and as new P-selectin is being expressed on recently activated platelet [40]. This study finding echoes results found by Vérickel et al. [17] whom also discovered hyperactive platelets in metabolically controlled diabetics without cardiovascular complications. The diabetic subjects with cardiovascular disease, recruited in this study were those

---

**Table 2 Baseline demographic data and clinical characteristics of the study population**

| Variable                        | Controls (n = 30) | Diabetics without CVD (n = 30) | Diabetics with CVD (n = 30) |
|---------------------------------|------------------|-------------------------------|-----------------------------|
| Age, years                      | 25 ± 9.64        | 53 ± 13.7                     | 61 ± 9.4                    |
| Males, n (%)                    | 6 (20)           | 11 (37)                       | 20 (67)                     |
| Females, n (%)                  | 24 (80)          | 19 (63)                       | 10 (33)                     |
| Hypertension, n (%)             | 17 (57)          | 15 (50)                       | 15 (50)                     |
| Diabetic treatment              |                  |                               |                             |
| Insulin, n (%)                  | 5 (17)           | 3 (10)                        |                             |
| Oral agents only, n (%)         | 16 (53)          | 12 (40)                       |                             |
| Oral and insulin, n (%)         | 9 (30)           | 15 (50)                       |                             |
| HBA1c %a                        | 9.0 ± 2.6        | 8.5 ± 1.7                     |                             |
| Cardiovascular complications    |                  |                               |                             |
| Previous MI, n (%)              |                  | 19 (63)                       |                             |
| PAD, n (%)                      | 2 (7)            |                               |                             |
| CABG, n (%)                     | 9 (30)           |                               |                             |
| Essential medication            |                  |                               |                             |
| ACEI, n (%)                     | 10 (33)          | 20 (67)                       |                             |
| Ca-antagonist, n (%)            | 8 (27)           | 3 (10)                        |                             |
| B-blocker, n (%)                | 3 (10)           | 11 (37)                       |                             |
| Nitrates, n (%)                 | 1 (3)            | 14 (47)                       |                             |
| Statins, n (%)                  | 10 (33)          | 25 (83)                       |                             |
| Disprin, n (%)                  | 6 (20)           | 20 (67)                       |                             |
| Warfarin, n (%)                 | 2 (7)            | 5 (17)                        |                             |

Data expressed as mean ± (SD) or n (%)

MI myocardial infarction, PAD peripheral arterial disease, CABG coronary artery bypass grafting, ACEI angiotensin converting enzyme inhibitor, Ca-antagonist calcium antagonist, HBA1c haemoglobin A1c

*a Not all 60 subjects had this test completed (results are available for 50 % of the subjects)
with ischaemic events many months and years prior to recruitment into this study. Our finding is in keeping with persistently hyperactivated platelets.

The CD63 MoAb recognizes the activation-specific fusion of the lysosomal granule membrane with the plasma membrane, therefore it only binds on the surface of activated platelets and is a useful tool to use in the identification of activated platelets [41]. In our study CD63 percentage activated platelets were significantly increased compared to the healthy controls. The diabetic group with cardiovascular complication showed the greatest percentage of platelet activation (61.24 % activation) while the diabetic group without cardiovascular complications showed a slightly lower activation percentage (54.39 % activation), as shown in Fig. 2. It appears as if CVD may play a role in platelet hyperactivation with lysosomal involvement.

**Conclusion**

This study adds to the body of evidence that diabetic patients have ‘angry platelets’. Platelet membrane markers and percentage activated platelets were increased in

**Table 3** Analysis of control and diabetic groups (with or without CVD), results presented as mean ± standard deviation (SD) of MCFI and percentage activated platelets

| MoAb                | Controls (n = 30) | Diabetes without CVD (n = 30) | Diabetes with CVD (n = 30) |
|---------------------|------------------|------------------------------|---------------------------|
| CD41-PE             | 21.08 ± 8.74     | 40.18 ± 14.56*               | 47.81 ± 24.49*            |
| CD42b-PE            | 14.43 ± 1.84     | 24.78 ± 11.98*               | 24.09 ± 7.27*             |
| CD62P-PE X-mean     | 30.86 ± 11.37    | 17.96 ± 1.95*                | 17.79 ± 2.266*            |
| CD62P-PE % activated platelets | 71.01 ± 16.20 | 92.65 ± 3.67*                | 92.11 ± 4.31*             |
| CD63-PE X-mean      | 16.40 ± 3.32     | 13.05 ± 3.68**               | 13.38 ± 3.12**            |
| CD63-PE % activated platelets | 37.84 ± 17.59 | 54.39 ± 32.92**              | 61.24 ± 29.73**           |

n = 10,000 platelets total analysed for each participant of each group
Statistically significant differences: * p < 0.001, ** p < 0.005

**Fig. 1** Micrographs showing representative platelets in (a) a typical platelet as seen in a healthy individual where platelets are disc-shaped with a few pseudopodia formation due to contact activation, b Type II diabetes without CVD, arrow shows platelet spreading and pseudopodia formation; c Platelets from type II diabetes with CVD now showing extensive spreading and microparticle formation (arrow). Scale bar 1 μm
diabetics with and without CVD. These results support and confirm the numerous papers suggesting that platelets play an important and possibly key role in the inflammatory profile of diabetic and cardiovascular patients and their health should play a key role in a patient-oriented precision medicine approach.

**Authors' contributions**

JNF, ACS and IM prepared the blood sample for microscopy and flow cytometry analysis. PS and EP contributed equally to microscopy analysis and writing of the manuscript. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Ethics, consent and permissions**

Ethical approval was granted at the University of Pretoria (Human Ethics Committee: Faculty of Health Sciences): E. Pretorius and P. Soma. All participants filled in informed consent forms.

**Role of funding source**

Funding was obtained from the National Research Foundation (NRF) (South Africa); the source was in no way involved in any part of this manuscript. No payment was received for the writing of this manuscript.

**Received:** 21 January 2016  
**Accepted:** 23 March 2016  
**Published online:** 31 March 2016

**References**

1. Alexandru N, Popov D, Georgescu A. Platelet dysfunction in vascular pathologies and how can it be treated. Thromb Res. 2012;129(2):116–26.
2. George JN. Platelets. Lancet. 2000;355(9214):1531–9.
3. Kanamori S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J. 2001;22(17):1561–71.
4. Cerletti C, Tamburelli C, Izzii B, Gianfagna F, de Gaetano G. Platelet-leukocyte interactions in thrombosis. Thromb Res. 2012;129(3):263–6.
5. Ghoshal K, Bhattacharyya M. Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. Sci World J. 2014;2014:781857.
6. Shi G, Morrell CN. Platelets as initiators and mediators of inflammation at the vessel wall. Thromb Res. 2011;127(5):387–90.
7. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol. 2003;23(12):1213–7.
8. Balusubramaniam K, Viswanathan GN, Marshall SM, Zaman AG. Increased atherosclerotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antplatelet therapy. Cardiol Res Pract. 2012;2012:909154.
9. Padmavathi P, Reddy VD, Maturu P, Varadacharyulu Y. Smoking-induced alterations in platelet membrane fluidity and Na(+)/Ca(2+) ATPase activity in chronic cigarette smokers. J Atheroscler Thromb. 2010;17(6):619–27.
10. Greaves M. Coagulation abnormalities and cerebral infarction. J Neurol Neurosurg Psychiatry. 1993;56(5):433–9.
11. van Rooy M, Duim W, Ehlers R, Buys AV, Pretorius E. Platelet hyperactivity and fibrin clot structure in metabolic syndrome-induced transient ischemic attack: a microscopy and thromboelastography study. Cardiovasc Diabetol. 2015;14(1):86.
12. Muller KA, Chatterjee M, Rath D, Geiser T. Platelets, inflammation and anti-inflammatory effects of antplatelet drugs in ACS and CAD. Thromb Haemost. 2015;114(3):498–518.
13. Ed Rainger G, Chimen M, Harrison MJ, Yates CM, Harrison P, Watson SP, Lordkipanidze M, Nash GB. The role of platelets in the recruitment of leukocytes during vascular disease. Platelets. 2015;26(6):507–20.
14. Viswanathan GNZA. Cardiovascular disease in patients with type 2 diabetes mellitus. J Clin Prev Cardiol. 2013;4:618–95.
15. Saboor M, Monnuddin M, Ilyas S. Comparison of platelet CD Markers between normal individuals and untreated patients with type 2 diabetes mellitus. J Hematol Thromb Dis. 2013;2(3):2.
16. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med. 2007;262(2):157–72.
17. Vericel E, Janczul C, Carreras M, Moulin P, Lagarde M. Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. Diabetes. 2004;53(4):1046–51.
18. Gawaz M, Reininger A, Neumann FJ. Platelet function and platelet-leukocyte adhesion in symptomatic coronary heart disease. Effects of intravenous magnesium. Thromb Res. 1996;83(5):341–8.
19. Smith NM, Pathansali R, Bath PM. Platelets and stroke. Vasc Med. 1999;4(3):165–72.
20. Marquardt L, Ruf A, Mansmann U, Winter R, Schuler M, Buggle F, Mayer H, Graj A. Course of platelet activation markers after ischemic stroke. Stroke. 2002;33(1):2570–4.
21. Pittillo RM. Cigarette smoking, endothelial injury and cardiovascular disease. Int J Exp Pathol. 2000;81(4):219–30.
22. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferranini E, Halcox J, Kowisik W, Luscher TF, Mancia G, Natali A, et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the working group on endothelins and endothelial dysfunction of the European society of hypertension. J Hypertens. 2005;23(2):233–46.
23. Yanbaeva DG, Denttner MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects of smoking. Chest. 2007;131(5):1557–66.
24. Knight-Lozano CA, Young CG, Burow DL, Hu ZY, Uyeminami D, Pinkerton KE, Ischiropoulos H, Ballinger SW. Cigarette smoke exposure and hypercholesterolemia increase mitochondrial damage in cardiovascular tissues. Circulation. 2002;105(7):849–54.
25. Carty CS, Soloway PD, Kayastha S, Bauer J, Marsan B, Ricotta JJ, Dryjski M. Nicotine and cotinine stimulate secretion of basic fibroblast growth factor. Blood. 2004;103(4):1303–20.
26. Marquardt L, Ruf A, Mansmann U, Winter R, Schuler M, Buggle F, Mayer H, Graj A. Course of platelet activation markers after ischemic stroke. Stroke. 2002;33(1):2570–4.
27. Hunter KA, Garlick PJ, Burow DL, Hu ZY, Uyeminami D, Pinkerton KE, Ischiropoulos H, Ballinger SW. Cigarette smoke exposure and hypercholesterolemia increase mitochondrial damage in cardiovascular tissues. Circulation. 2002;105(7):849–54.
28. Carty CS, Soloway PD, Kayastha S, Bauer J, Marsan B, Ricotta JJ, Dryjski M. Nicotine and cotinine stimulate secretion of basic fibroblast growth factor. Blood. 2004;103(4):1303–20.
30. Eibl N, Krugluger W, Streit G, Schrattbauer K, Hopmeier P, Schernthaner G. Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. Eur J Clin Invest. 2004;34(3):205–9.

31. Tschope D, Schultheiss HP, Kolarov P, Schwippert B, Dannehil K, Nieuwenhuis HK, Kehrel B, Strauer B, Gries FA. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation. 1993;88(1):37–42.

32. McEver RP. P-selectin/PSGL-1 and other interactions between platelets, leukocytes and endothelium. In: Platelets, vol. 2007. San Diego: Elsevier/Academic Press; 2007. p. 231–49.

33. Hughes A, McLerry BA, Wilkinson L, Goldstone AH, Lewis D, Bloom A. Diabetes, a hypercoagulable state? Hemostatic variables in newly diagnosed type 2 diabetic patients. Acta Haematol. 1983;69(4):254–9.

34. Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Haemost. 1991;65(5):467–73.

35. Nieuwenhuis HK, van Oosterhout JJ, Rozemuller E, van Iwaarden F, Sixma JJ. Studies with a monoclonal antibody against activated platelets: evidence that a secreted 53,000-molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation. Blood. 1987;70(3):838–45.

36. Kraft P, De Meyer SF, Kleinschnitz C. Next-generation antithrombotics in ischemic stroke: preclinical perspective on ‘bleeding-free antithrombosis’. J Cereb Blood Flow Metab. 2012;32(10):1831–40.

37. De Meyer SF, Schwarz T, Schatzberg D, Wagner DD. Platelet glycoprotein Ibalpha is an important mediator of ischemic stroke in mice. Exp Transl Stroke Med. 2011;3:9.

38. Mu FT, Andrews RK, Arthur JF, Munday AD, Cranmer SL, Jackson SP, Stomski FC, Lopez AF, Berntd MC. A functional 14-3-3zeta-independent association of PI3-kinase with glycoprotein Ib alpha, the major ligand-binding subunit of the platelet glycoprotein Ib-IX-V complex. Blood. 2008;111(9):4580–7.

39. Blann AD, Draper Z. Platelet activation as a marker of heart attack. Clin Chim Acta. 2011;412(11–12):841–2.

40. Inoue T. Cigarette smoking as a risk factor of coronary artery disease and its effects on platelet function. Tob Induc Dis. 2004;2(1):27–33.

41. Metzelaar M, Wijngaard P, Peters P, Sixma JJ, Nieuwenhuis HK, Clevers H. CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem. 1991;266(5):3239–45.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit